Literature DB >> 21858571

Ki-67 and Bax expression in esophageal mucosa might have implications in ablative therapies for Barrett's esophagus, dysplasia, and adenocarcinoma.

Jannis Kountouras, Dimitrios Chatzopoulos, Christos Zavos, Georgia Deretzi, Stergios A Polyzos, Emmanuel Gavalas, Philippos Klonizakis, Elizabeth Vardaka, Panagiotis Katsinelos, Christos Stergiopoulos, John Moschos, Evaggelia Giartza-Taxidou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 21858571     DOI： 10.1007/s00464-011-1864-1

Source DB:  PubMed          Journal:  Surg Endosc        ISSN： 0930-2794            Impact factor:   4.584


× No keyword cloud information.
  14 in total

1.  Risk of extra-oesophageal malignancies in Barrett's oesophagus.

Authors:  J Kountouras; C Zavos; D Chatzopoulos
Journal:  Scand J Gastroenterol       Date:  2004-12       Impact factor: 2.423

Review 2.  Epidemiology of esophageal adenocarcinoma.

Authors:  Manuel Pera; Carlos Manterola; Oscar Vidal; Luis Grande
Journal:  J Surg Oncol       Date:  2005-12-01       Impact factor: 3.454

3.  Helicobacter pylori and gastro-oesophageal reflux disease.

Authors:  Jannis Kountouras; Christos Zavos; Dimitrios Chatzopoulos; Panagiotis Katsinelos
Journal:  Lancet       Date:  2006-09-16       Impact factor: 79.321

4.  Diet and risk of esophageal cancer by histologic type in a low-risk population.

Authors:  A Tzonou; L Lipworth; A Garidou; L B Signorello; P Lagiou; C Hsieh; D Trichopoulos
Journal:  Int J Cancer       Date:  1996-11-04       Impact factor: 7.396

5.  Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population.

Authors:  A Garidou; A Tzonou; L Lipworth; L B Signorello; V Kalapothaki; D Trichopoulos
Journal:  Int J Cancer       Date:  1996-11-04       Impact factor: 7.396

6.  Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.

Authors:  Christopher John Lewis; Sri Ganeshamurthy Thrumurthy; Susan Pritchard; Gordon Armstrong; Stephen Edwin Arthur Attwood
Journal:  Surg Endosc       Date:  2011-02-27       Impact factor: 4.584

7.  Eradication of Helicobacter pylori might halt the progress to oesophageal adenocarcinoma in patients with gastro-oesophageal reflux disease and Barrett's oesophagus.

Authors:  Jannis Kountouras; Dimitrios Chatzopoulos; Christos Zavos
Journal:  Med Hypotheses       Date:  2006-12-29       Impact factor: 1.538

Review 8.  New molecular concepts of Barrett's esophagus: clinical implications and biomarkers.

Authors:  Athanassios Kyrgidis; Jannis Kountouras; Christos Zavos; Dimitrios Chatzopoulos
Journal:  J Surg Res       Date:  2005-05-15       Impact factor: 2.192

9.  Bax upregulation may provide a rationale for the low incidence of esophageal adenocarcinoma in a Greek cohort of patients with Barrett's esophagus.

Authors:  Dimitrios Chatzopoulos; Athanasios Kyrgidis; Jannis Kountouras; Christos Zavos; Epaminondas Molyvas; Ioannis Venizelos
Journal:  Hepatogastroenterology       Date:  2007 Apr-May

10.  CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett's esophagus in a population with high H. pylori infection rate.

Authors:  Angel Ferrández; Rafael Benito; Juan Arenas; María Asunción García-González; Federico Sopeña; Javier Alcedo; Javier Ortego; Ricardo Sainz; Angel Lanas
Journal:  BMC Gastroenterol       Date:  2006-02-16       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.